|
|
|
|
|
|
|
M T W Thu F |
|
1 October, 2026 |
|
|
sponsored by
|
|
|
|
Complex Synthetic Molecule Development and Manufacturing
|
| Accelerating complex synthetic molecule development requires the right expertise, technology, and scale. Discover how Cambrex and Snapdragon Chemistry combine advanced process development, automation, proprietary technologies, and state-of-the-art analytical capabilities to support peptides, oligonucleotides, conjugates, polymers, and other complex modalities. Learn how innovative peptide crystallization and liquid phase peptide synthesis approaches can improve quality, scalability, sustainability, and speed from development through cGMP manufacturing. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Last week, Anthropic said its AI discovered a new class of enzymes, conducting original science for the first time ever. A few days later, a University of Copenhagen researcher said he’d already discovered enzymes in that class. Andrew Dunn spoke with the Anthropic researchers, who insist their model didn’t copy the scientist’s work. Read his interview for details. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
Eric Kauderer-Abrams, Anthropic’s head of life sciences |
|
|
|
by Andrew Dunn
|
Last week, Anthropic said its AI system made its first scientific discovery. Claude agents had discovered a new enzyme system, the AI giant said, publicizing the findings... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Eli Lilly is walking away from Foghorn Therapeutics' "synthetic lethality" drug development, and the small biotech is reducing its headcount by 40% as a result... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Novo, Nektar, MindRank, Mabwell Bioscience, Atara Biotherapeutics, Pierre Fabre, Monte Rosa and Skopos Bio. United Therapeutics wins court battle: A federal court... | |
|
|
|
 |
|
Sanofi CEO Belén Garijo (L) and Regeneron CEO Leonard Schleifer |
|
|
|
by Reynald Castaneda
|
As the patent cliff for Dupixent draws closer, Sanofi is turning back to the partnership that built the megablockbuster. The French pharma will pay $1... | |
|
|
|
|
|
|
by Kyle LaHucik
|
New York City drug developer Kallyope is rebranding as TriGemX Bio as it focuses solely on treating migraine. To support the restructured company and its... | |
|
|
|
|
|
